Akums Drugs Q1 Profit Surges 55 percent as CDMO Drives FY27 Growth

Akums Drugs and Pharmaceuticals has started FY27 on a strong note, with Q1 profit surging 55 percent year-on-year.

The company reported operating revenue of Rs. 1,167 crore in the June quarter. Revenue stood at Rs. 1,024 crore in Q1 FY26. Profitability also improved across key metrics during the quarter.

EBITDA rose 35.4 percent to Rs. 175 crore. The EBITDA margin expanded to 15 percent from 12.6 percent last year.

The company’s CDMO business remained the main growth driver during the quarter. Higher volumes and improved API prices supported its performance.

Akums Drugs Revenue and Profit Rise in Q1 FY27

Akums Drugs reported a 13.9 percent year-on-year rise in operating revenue. The revenue reached Rs. 1,167 crore in Q1 FY27. The company reported EBITDA of Rs. 175 crore during the quarter. This was 35.4 percent higher than Rs. 129 crore last year. The EBITDA margin also improved during the quarter. It reached 15 percent compared with 12.6 percent in Q1 FY26. PAT increased to Rs. 101 crore from Rs. 65 crore a year earlier. This represents a 55.4 percent year-on-year increase in profit. The PAT margin also expanded to 8.4 percent from 6.2 percent in the year-ago quarter.

Akums also delivered sequential growth across its key profitability metrics.

• EBITDA increased from Rs. 152 crore in Q4 FY26 to Rs. 175 crore.
• PAT rose from Rs. 81 crore to Rs. 101 crore.
• EBITDA margin improved to 15 percent during Q1 FY27.
• PAT margin increased to 8.4 percent.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

CDMO Business Powers Akums Drugs Growth

Akums’ CDMO business continued to be the company’s main growth engine in Q1 FY27. CDMO revenue rose to Rs. 964 crore from Rs. 813 crore in Q1 FY26. The business therefore recorded strong year-on-year growth during the quarter. CDMO EBITDA also increased 36.8 percent year-on-year. It reached Rs. 163 crore compared with Rs. 119 crore last year. The company linked the performance to continued volume growth and improved API prices. Strong demand also supported the business during the quarter.

Sanjeev Jain, Co-Founder & Director, said FY27 began on a strong and encouraging note. He pointed to healthy demand and continued client trust in Akums. He said the CDMO performance reflects Akums’ position as a preferred manufacturing partner. The company’s CDMO performance remains important for its overall growth outlook. Rising revenue and EBITDA also supported the improvement in consolidated profitability.

Akums Eyes Stronger CDMO Position in FY27

Akums Drugs plans to build on its strong start to the financial year. The company is focused on strengthening its CDMO leadership. It also plans to scale high-value capabilities and improve operational efficiency. Sandeep Jain, Founder & MD, said the company remains focused on operational excellence. He also highlighted its strong pipeline and prudent capital allocation. According to the company, these factors position Akums for sustainable growth in the coming years.

The Q1 FY27 results show improvement in both revenue and profitability. The continued performance of the CDMO segment will remain a key growth factor.

Key Highlights

• Operating revenue rose 13.9 percent to Rs. 1,167 crore.
• EBITDA increased 35.4 percent to Rs. 175 crore.
• PAT jumped 55.4 percent to Rs. 101 crore.
• CDMO revenue reached Rs. 964 crore.
• CDMO EBITDA rose 36.8 percent to Rs. 163 crore.
• EBITDA margin expanded to 15 percent.
• PAT margin increased to 8.4 percent.
• Higher volumes and better API prices supported CDMO growth.